SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Taf Spray 28.5 mg/g Cutaneous spray, solution

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each g contains:

Active substances:

Thiamphenicol 28.5 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Curcumine (E100)	0.5 mg
Acetone
Dimethylacetamide
Copolymer of vinylpyrrolidone and vinyl acetate (30/70)
Ethanol
Triacetin
Dimethylether

Clear yellow spray.

3. CLINICAL INFORMATION

3.1 Target species

Horses, cattle, goats, sheep, pigs, mink, rabbits.

3.2 Indications for use for each target species

In all target species:

- Treatment of superficial wound infections caused by micro-organisms susceptible to thiamphenicol.

In cattle, goats and sheep:

- Treatment of infections of the claw and hoof such as foot rot, interdigital dermatitis, digital dermatitis caused by micro-organisms susceptible to thiamphenicol.

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients. See also section 3.12 (Withdrawal periods).

3.4 Special warnings

Clean the affected area thoroughly before spraying. After administration of the veterinary medicinal product the animal should be kept on dry ground for at least one hour.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Protect the eyes when spraying in the vicinity of the head. The animal should be prevented from licking the treated area, or treated areas on other animals.

Use of the product should be based on susceptibility testing and take into account official and local antimicrobial policies. Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacterial resistance.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental eye contact, the veterinary medicinal product may cause irritation. Personal protective equipment consisting of safety glasses should be worn when handling the veterinary medicinal product. Do not spray towards a person. If irritation occurs, seek medical advice and show the label or package leaflet to the physician.

Asthma and rhinitis may occur following inhalation. Do not inhale vapours. Apply the veterinary medicinal product in the open air, or in a sufficiently ventilated area.

This veterinary medicinal product can be toxic when ingested.

Contact with the treated area should be avoided and children should not be allowed to play with treated pet animals until the application site is dry.

Do not eat, drink or smoke during administration.

Hypersensitivity (allergy) to thiamphenicol may occur rarely. People with known hypersensitivity to thiamphenicol should avoid contact with the veterinary medicinal product. Should symptoms occur such as swelling of the face, lips or eyes or difficulty in breathing, seek urgent medical attention.

Wash hands after use.

Do not spray on an open flame or other ignition source. Do not pierce or burn, even after use.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Horses, cattle, goats, sheep, pigs, mink, rabbits:

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the immediate packaging or package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Pregnancy and lactation:

Use only in accordance with the benefit-risk assessment by the responsible veterinarian.

3.8 Interaction with other medicinal products and other forms of interaction

None known.

3.9 Administration routes and dosage

Cutaneous use.

Shake the container thoroughly before spraying.

Spray the solution on the affected area for 3 seconds (equivalent to approximately 45 mg thiamphenicol) once a day. Treatment can be repeated depending on the healing process, up to 3 consecutive days.

The container should be held at a distance of approximately 15 – 20 cm from the area to be sprayed. For optimal use, wounds should be cleaned before application. The spray container is suitable to be used in upright and inverted positions.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

None known.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Meat and offal:

- horses, cattle, goats, sheep, rabbits: zero days.

- pigs: 14 days.

Milk: zero hours.

Do not use on the udder of lactating animals if milk is intended for human consumption.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QD06AX

4.2 Pharmacodynamics

Thiamphenicol is a broad-spectrum antimicrobial agent, structurally similar to chloramphenicol. It is bacteriostatic for both Gram-positive and Gram-negative bacteria and acts by blocking the protein synthesis.

The most common mechanism of resistance to thiamphenicol is acquired by microorganisms via a plasmid-encoded acetyltransferase that inactivates the drug. Cross-resistance of thiamphenicol with chloramphenicol is complete in bacteria which possess chloramphenicol acetyltransferases (CATs). Acetylation of the hydroxyl groups by CATs prevents drug binding to the 50S ribosomal subunit. There are also other mechanisms of resistance, such as efflux systems, inactivation by phophotransferases, and mutation of the target site or permeability barriers. The CAT genes are commonly found on plasmids and most of these plasmids carry one or more additional resistance genes.

4.3 Pharmacokinetics

The absorption of thiamphenicol following dermal administration is negligible.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

None known.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

5.3 Special precautions for storage

Extremely flammable aerosol. Pressurised container: May burst if heated.

Protect from sunlight. Do not expose to temperatures exceeding 50°C.

Keep away from heat/hot surfaces/sparks/open flames and other ignition sources. No smoking.

5.4 Nature and composition of immediate packaging

50 ml (containing 24,9 g solution without propellant equivalent to 0.71 g of thiamphenicol) aluminium pressurised containers with epoxy phenolic pigment lacquer.

150 ml (containing 74,7 g solution without propellant equivalent to 2.13 g of thiamphenicol) aluminium pressurised containers with epoxy phenolic pigment lacquer.

200 ml (containing 99,6 g solution without propellant equivalent to 2.84 g of thiamphenicol) aluminium pressurised containers with epoxy phenolic pigment lacquer.

300 ml (containing 149,4 g solution without propellant equivalent to 4.26 g of thiamphenicol) aluminium pressurised containers with epoxy phenolic pigment lacquer.

400 ml (containing 199,2 g solution without propellant equivalent to 5.68 g of thiamphenicol) aluminium pressurised containers with epoxy phenolic pigment lacquer.

• Polyamide/polyethylene valve mechanism integrated in aluminium container top

• Polypropylene spray nozzle with polyoxymethylene nebuliser.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Eurovet Animal Health B.V.

7. MARKETING AUTHORISATION NUMBER

Vm 16849/4051

8. DATE OF FIRST AUTHORISATION

13 January 2015

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

September 2026

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.

Approved 14 September 2026